Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock GNCA vs. SCPS, VRPX, STAB, EVLO, CMRA, GNCAQ, ARDS, AMPE, PXMD, and CALAShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Virpax Pharmaceuticals (VRPX), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Aridis Pharmaceuticals (ARDS), Ampio Pharmaceuticals (AMPE), PaxMedica (PXMD), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Its Competitors Scopus BioPharma Virpax Pharmaceuticals Statera Biopharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Aridis Pharmaceuticals Ampio Pharmaceuticals PaxMedica Calithera Biosciences Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is SCPS or GNCA more profitable? Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Genocea Biosciences N/A -182.88%-62.76% Which has stronger valuation and earnings, SCPS or GNCA? Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/A Does the media refer more to SCPS or GNCA? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Genocea Biosciences Neutral Do institutionals and insiders hold more shares of SCPS or GNCA? 0.6% of Genocea Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, SCPS or GNCA? Scopus BioPharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500. SummaryScopus BioPharma beats Genocea Biosciences on 4 of the 7 factors compared between the two stocks. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6K$283.66M$5.77B$9.91BDividend YieldN/AN/A6.67%4.51%P/E Ratio0.00N/A75.7426.65Price / SalesN/A474.09557.21121.56Price / CashN/A22.4437.1158.92Price / BookN/A10.9911.446.07Net Income-$33.20M-$115.81M$3.28B$266.32M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070SCPSScopus BioPharmaN/A$0.00+66.7%N/AN/A$21KN/A0.009VRPXVirpax Pharmaceuticals0.1019 of 5 stars$0.01-9.8%N/A-99.9%$14KN/A0.007STABStatera BiopharmaN/A$0.00+100.0%N/A-83.3%$11KN/A0.0020Gap UpHigh Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Options VolumeCMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070ARDSAridis PharmaceuticalsN/A$0.00-50.0%N/AN/A$5KN/A0.0030Gap DownAMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020PXMDPaxMedicaN/A$0.00flatN/AN/A$2KN/A0.002CALACalithera BiosciencesN/A$0.00flatN/A-99.0%$1KN/A0.0060Gap Down Related Companies and Tools Related Companies SCPS Competitors VRPX Competitors STAB Competitors EVLO Competitors CMRA Competitors GNCAQ Competitors ARDS Competitors AMPE Competitors PXMD Competitors CALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNCA) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNCA Stock Alerts